Pancreatic Cancer Symptoms, Stages and Treatment
In this article
What Is Pancreatic Cancer?
When pancreatic cancer is mentioned, the term almost always refers to pancreatic ductal adenocarcinoma (PDAC)— accounting for the vast majority of all cases and arising from the pancreas's exocrine tissue that produces digestive enzymes, PDAC is also the main focus of this guide. As of today (26 August 2026), one of the most important developments in decades has occurred in this field: daraxonrasib, an entirely new drug class that works independently of KRAS mutation type, has received FDA approval with groundbreaking survival data in metastatic pancreatic cancer. Although pancreatic cancer remains one of the most challenging cancers in its course, the new diagnostic/treatment tools covered in this guide offer an increasing number of options for managing the disease.
Rarer tumor types besides PDAC may also develop in the pancreas: pancreatic neuroendocrine tumors (pNETs) have entirely different biology, staging and treatment approaches and are discussed in detail in our separate guide . Much rarer exocrine tumor types such as acinar cell carcinoma also exist; they are not addressed in this guide.
Pancreatic Anatomy and Function
The pancreas is an organ approximately 15 cm long, located behind the stomach deep within the abdominal cavity, and is divided into three main regions: the head adjacent to the duodenum, the first part of the small intestine; the body (corpus) extending in the middle; and the tail adjacent to the spleen. This anatomical distinction is clinically very important: where a tumor lies in the pancreas directly determines both the nature of symptoms (head tumors cause jaundice by blocking the bile duct, whereas body/tail tumors cause symptoms much later) and the type of surgery performed.
The pancreas has two main functions: exocrine function — producing digestive enzymes (amylase, lipase, protease) and secreting them into the small intestine — and endocrine function — producing hormones that regulate blood sugar, such as insulin and glucagon, through cells in the islets of Langerhans. PDAC arises from exocrine tissue (mostly the cells lining pancreatic ducts); however, both exocrine and endocrine functions may be impaired as the tumor grows or when a large proportion of pancreatic tissue is surgically removed — explaining why enzyme replacement therapy and diabetes management, discussed later in this guide, are particularly important in this disease group.
How Common Is It? (Current Statistics)
According to the International Agency for Research on Cancer's (IARC) "Global cancer statistics 2024" report (Sung H, et al., CA: A Cancer Journal for Clinicians, published on 8 July 2026, DOI: 10.3322/caac.70090), based on 2024 data, approximately 531.318 new pancreatic cancer cases (ranked 11th in incidence) and 490.786 deaths from pancreatic cancer (ranked 6th among cancer deaths) were reported. These figures clearly reveal how disproportionately fatal pancreatic cancer is: the incidence-death ratio is approximately 0,92 — meaning almost as many deaths occur as newly diagnosed cases. In the regional distribution, 45,9% of cases occur in Asia, 27,7% in Europe and 13,6% in North America.
According to the American Cancer Society's "Cancer Statistics, 2026" report (Siegel RL, et al., CA: A Cancer Journal for Clinicians, published on 13 January 2026, DOI: 10.3322/caac.70043), in 2026, approximately 67.530 new pancreatic cancer cases and 52.740 deaths are expected in the USA; pancreatic cancer is the 3rd most common cause of cancer deaths in both men and women (after lung and colorectal cancer). Stage-specific 5-year relative survival (SEER, 2015-2021 diagnosis cohort): 44% in localized disease, 17% in regional spread, only 3% in distant metastases; across all stages, only %13 — this rate makes pancreatic cancer one of the diseases with the lowest overall survival among all major cancer types. Only approximately 17% of patients have localized disease at diagnosis; this low proportion explains why the disease is generally detected at an advanced stage (because symptoms arise late and nonspecifically).
According to the GLOBOCAN 2024 Turkey country profile, approximately 6.110 new pancreatic cancer cases and 5.813 deaths are reported annually in Turkey, placing pancreatic cancer 11th in incidence among all cancers — with a death rate nearly equal to its incidence, consistent with the global trend.
Risk Factors
- Smoking — the best-established modifiable risk factor, increases risk approximately 2-fold
- Obesity / high body mass index
- Long-standing type 2 diabetes
- Chronic pancreatitis (particularly a substantially increased risk with hereditary pancreatitis)
- Heavy and long-term alcohol consumption (mainly through chronic pancreatitis)
- Family history of pancreatic cancer (a hereditary component is present in approximately 5-10% of cases)
In people over age 50, diabetes that appears suddenly or worsens unexpectedly without another risk factor may, in some patients, be an early paraneoplastic finding of pancreatic cancer due to tumor-induced beta cell dysfunction. New-onset diabetes, especially with unexplained weight loss, is a warning sign that should direct the physician's attention to the pancreas.
Hereditary Syndromes and Familial Risk
| Syndrome / Gene | Associated Cancer Risk |
|---|---|
| BRCA1 / BRCA2 | Hereditary breast-ovarian cancer syndrome; BRCA2 carries a more pronounced pancreatic cancer risk than BRCA1 — the most clinically important group because it determines sensitivity to platinum-based chemotherapy and eligibility for PARP inhibitor (olaparib) treatment |
| PALB2 | BRCA2's partner in the homologous recombination repair pathway; carries similar clinical implications (HRD positivity) |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2) | Associated with the rare MSI-H/dMMR pancreatic cancer subgroup — possibility of an exceptional response to pembrolizumab |
| FAMMM syndrome (CDKN2A/p16) | Familial atypical multiple mole-melanoma syndrome; one of the syndromes with the highest known relative risk of pancreatic cancer |
| Peutz-Jeghers syndrome (STK11/LKB1) | Has one of the highest relative risks of pancreatic cancer reported in the literature |
| Hereditary pancreatitis (PRSS1, SPINK1) | Recurrent pancreatitis attacks from childhood; substantially increased lifetime pancreatic cancer risk, especially when combined with smoking |
The NCCN guideline was updated in 2019 and began recommending, regardless of family history, germline (hereditary) genetic testing for all patients diagnosed with pancreatic cancer — unlike the previous approach (a recommendation at the level of "may be considered" only in those with a family history), this is now part of standard care. These tests guide both the patient's treatment selection (BRCA/PALB2 positivity affects platinum chemotherapy and PARP inhibitor use) and risk assessment for first-degree relatives. Our separate article on familial pancreatic cancer addresses this topic in more detail.
Precursor (Precancerous) Lesions
The vast majority of PDAC develops stepwise from detectable precursor lesions; recognizing these lesions offers an opportunity to intervene before cancer develops.
PanIN (Pancreatic Intraepithelial Neoplasia)
At the 2014 Baltimore Consensus Meeting, the classic 3-tier system (PanIN-1A/1B, PanIN-2, PanIN-3) was simplified into a 2-tier system: low-grade PanIN (formerly 1A/1B/2) and high-grade PanIN (formerly PanIN-3/carcinoma in situ). High-grade PanIN has a substantial likelihood of progression to invasive PDAC and is generally detected near invasive cancer rather than in isolation.
IPMN (Intraductal Papillary Mucinous Neoplasm)
IPMN is a mucin (mucus)-producing cystic tumor arising from cells lining the pancreatic duct and is classified as main-duct type (MD-IPMN), branch-duct type (BD-IPMN, approximately 80% of incidentally detected IPMNs) and mixed type . Our separate article on IPMN addresses this topic in detail.
The long-used Fukuoka consensus criteria (2006/2012/2017) were updated with the guideline published online in December 2023 (Ohtsuka T, et al., Pancreatology, 2024) 2024 International Evidence-Based Kyoto Guideline . A distinction is made between "high-risk stigmata" supporting surgical resection (obstructive jaundice with a cystic lesion in the pancreatic head; a strongly enhancing mural nodule ≥5mm or solid component; main pancreatic duct ≥10mm; suspicious/positive cytology) and "worrisome features" requiring closer surveillance (EUS±fine-needle aspiration) (history of acute pancreatitis, elevated CA19-9, new-onset/rapidly worsening diabetes within 1 year, cyst ≥30mm, mural nodule <5mm, thickened/enhancing cyst wall, main duct 5-9mm, abrupt duct diameter change with distal atrophy, lymphadenopathy, annual growth rate ≥2,5mm). An important practical change: it is now accepted that surveillance can be stopped for small branch-duct IPMNs stable for 5 years.
Mucinous Cystic Neoplasm (MCN)
Unlike IPMN, MCN is not connected to the pancreatic duct, occurs almost exclusively in women, typically lies in the body/tail region and requires "ovarian-type stroma" for diagnosis. Because of malignant potential, surgical resection is generally recommended, particularly for MCNs larger than 4 cm or containing a mural nodule.
Symptoms
- Painless jaundice (particularly in pancreatic head tumors, due to bile duct obstruction)
- Unexplained weight loss
- New-onset or suddenly worsening diabetes
- Pain radiating from the upper abdomen to the back (generally suggesting retroperitoneal/celiac plexus invasion)
- Loss of appetite, early satiety
- Unexplained deep vein thrombosis or migratory thrombophlebitis (Trousseau syndrome)
- New-onset, unexplained depression (may appear months before diagnosis in some patients)
A palpable, non-tender enlarged gallbladder with painless jaundice ("Courvoisier sign") suggests malignant distal biliary obstruction rather than gallstone disease and is a warning finding for a pancreatic head tumor. Our separate article on pancreatic cancer and jaundice addresses this topic in detail.
How Is It Diagnosed?
CA 19-9 Tumor Marker
CA 19-9 is the most widely used tumor marker in pancreatic cancer; it is valuable for monitoring treatment response and recurrence but has limited use in screening/early diagnosis because its specificity is low (it can also increase in benign biliary obstruction, pancreatitis and other gastrointestinal cancers) and its sensitivity in early-stage disease is poor.
Approximately 5-10% of the population is Lewis antigen-negative (Le(a-b-) blood group phenotype) and genetically, regardless of tumor burden, can never produce CA 19-9. In these patients, CA 19-9 levels may be normal even in active and advanced disease — a normal CA 19-9 result must therefore never be used alone to exclude pancreatic cancer.
Imaging and Tissue Diagnosis
Using the pancreatic protocol (thin-slice, dual-phase), computed tomography (CT)is the primary imaging method for detecting and staging the tumor and assessing vascular involvement (resectability). MRI/MRCP is complementary, particularly for characterizing cystic lesions (IPMN/MCN) and detecting liver metastases. Endoscopic ultrasound (EUS) with fine-needle aspiration/biopsy (FNA/FNB)is the primary method for obtaining a tissue diagnosis, especially in small lesions, and also allows detailed local staging. ERCP is used in this disease primarily for therapeutic rather than diagnostic purposes (placing a bile duct stent for obstructive jaundice). Staging laparoscopy is performed in selected patients, especially with borderline resectable/locally advanced disease or suspected occult metastases such as CA19-9 disproportionately high relative to imaging, to exclude radiologically invisible peritoneal/liver metastases before referring the patient for major surgery (Whipple).
Molecular (Biomarker) Tests
Testing biomarkers that directly guide treatment selection (alongside germline testing) is now considered standard in every patient diagnosed with metastatic pancreatic cancer:
| Biomarker | Frequency | Clinical Importance |
|---|---|---|
| KRAS mutation | In ~90% of PDAC (G12D is most common at codon 12, followed by G12V, G12R; G12C only ~1-2%) | Determines selection of KRAS-directed treatments (see daraxonrasib below) and the possibility of targeted treatment in the rare G12C subgroup |
| Germline/somatic BRCA1/2, PALB2 (HRD) | In a subgroup of patients | Determines sensitivity to platinum-based chemotherapy and eligibility for olaparib maintenance treatment |
| MSI-H / dMMR | ~1-2% (rare) | Possibility of an exceptional response to histology-independent (tumor-agnostic) treatment with pembrolizumab |
| NTRK gene fusions | Very rare (below 1%) | Determines eligibility for tumor-agnostic treatment with larotrectinib/entrectinib |
| NRG1 gene fusions | ~%3 | Determines eligibility for zenocutuzumab treatment (see below) |
| HER2 (ERBB2) amplification | Rare | Currently no approved HER2-targeted treatment in PDAC; in research |
Staging
In pancreatic cancer, the AJCC 8th edition TNM system determines formal staging and remains current (the AJCC 9th edition updates published in 2024 mainly concern neuroendocrine tumor staging and did not change the T/N/M categories for exocrine PDAC). However, the classification that more directly guides treatment decisions in daily clinical practice, based on the tumor's relationship with surrounding major vessels (particularly the superior mesenteric artery/vein, celiac artery, common hepatic artery and portal vein), is the resectability classification — the treatment approach below is explained based on this classification.
| Resectability Category | General Definition |
|---|---|
| Resectable | No tumor contact with the superior mesenteric artery (SMA), celiac artery or common hepatic artery; no superior mesenteric vein/portal vein contact or no distortion of normal vessel contour |
| Borderline resectable | Contact with ≤180° of the SMA or celiac artery circumference; reconstructible contact with the common hepatic artery; superior mesenteric vein/portal vein involvement suitable for reconstruction (including short-segment occlusion) |
| Locally advanced (unresectable) | Contact/encasement of >180° of the SMA and/or celiac artery circumference; superior mesenteric vein/portal vein involvement unsuitable for reconstruction; aortic involvement |
| Metastatic | Distant organ involvement present — surgery is not indicated regardless of local anatomy |
These four categories form the framework of the treatment plan, and the following treatment sections are organized according to this classification.
Surgical Treatment
- Whipple procedure (pancreaticoduodenectomy): performed for pancreatic head tumors; the pancreatic head, duodenum, lower bile duct, gallbladder (and part of the stomach in the classic technique) are removed together and the digestive tract is reconstructed — one of the most complex operations in gastrointestinal surgery, ideally performed at high-volume centers
- Distal pancreatectomy (usually with the spleen): performed for body/tail tumors
- Total pancreatectomy: performed in selected cases (for example, multifocal disease, IPMN involving the entire duct or when surgical margins cannot otherwise be cleared) — results in complete exocrine/endocrine insufficiency ("brittle" diabetes)
R0 resection (microscopically negative surgical margins) is a critical factor determining outcome; R1/R2 resections are associated with substantially worse prognosis. Surgery is performed only in resectable or borderline resectable disease (after shrinkage with neoadjuvant treatment); surgical outcomes have improved meaningfully only when combined with effective systemic treatment (adjuvant/neoadjuvant) — reflecting PDAC's high tendency toward micrometastatic spread even in apparently localized disease.
Adjuvant Treatment in Resectable Disease
Postoperative (adjuvant) systemic treatment is standard in resectable PDAC to reduce recurrence risk, and one of two main regimens is selected according to general performance status:
According to the PRODIGE 24/CCTG PA.6 study (Conroy T, et al., New England Journal of Medicine, 2018), in resected patients with good performance status, modified FOLFIRINOX (mFOLFIRINOX) substantially prolonged disease-free survival (21,6 versus 12,8 months; HR 0,58) and overall survival (54,4 versus 35,0 months; HR 0,64) compared with gemcitabine alone. These results made mFOLFIRINOX the standard adjuvant treatment in suitable patients (with good performance status).
According to the ESPAC-4 study (Neoptolemos JP, et al., Lancet, 2017), gemcitabine+capecitabine prolonged overall survival compared with gemcitabine alone (28,0 versus 25,5 months; HR 0,82; 5-year survival 28,8% versus 16,3%). This regimen is used as an important adjuvant option, particularly in patients who cannot tolerate the toxicity level of mFOLFIRINOX.
Neoadjuvant Treatment in Borderline Resectable and Locally Advanced Disease
In current practice, preoperative (neoadjuvant) systemic treatment is given in borderline resectable and some locally advanced patients, aiming both to shrink/downstage the tumor and to control micrometastatic disease early — generally with FOLFIRINOX or gemcitabine+nab-paclitaxel-based regimens.
According to the PREOPANC study (Versteijne E, et al., Journal of Clinical Oncology, 2020; long-term results 2022), neoadjuvant gemcitabine-based chemoradiotherapy prolonged overall survival compared with upfront surgery in resectable and borderline resectable patients (15,7 versus 14,3 months; HR 0,73) — particularly striking is that this difference grows substantially over time: 5-year survival 20,5% versus only 6,5%. Although PREOPANC provides important randomized evidence for the general validity of the preoperative treatment strategy, current practice is increasingly moving toward FOLFIRINOX or gemcitabine+nab-paclitaxel-based neoadjuvant chemotherapy rather than chemoradiotherapy.
Treatment of Locally Advanced (Unresectable) Disease
Chemotherapy forms the treatment backbone in locally advanced, unresectable disease (FOLFIRINOX or gemcitabine+nab-paclitaxel); radiotherapy/stereotactic body radiotherapy (SBRT) may be used for local control/pain management in selected patients.
According to the LAP07 study (Hammel P, et al., JAMA, 2016), in patients with controlled disease after 4 months of induction chemotherapy, no significant overall survival difference was found between continuing chemotherapy and switching to chemoradiotherapy (16,5 versus 15,2 months; HR 1,03) — the study was stopped early for this question. This is an important nuance: although radiotherapy/SBRT in locally advanced disease continues to be used pragmatically at many centers for local control or pain palliation, high-level evidence does not show that it prolongs overall survival.
First-Line Treatment in Metastatic Disease
One of two standard combination regimens is preferred in patients with good performance status:
According to the PRODIGE/ACCORD 11 study (Conroy T, et al., New England Journal of Medicine, 2011), FOLFIRINOX (5-FU/folinic acid/irinotecan/oxaliplatin) substantially prolonged overall survival in metastatic disease compared with gemcitabine alone (11,1 versus 6,8 months). This regimen has higher toxicity and is preferred mainly in patients with good general performance status.
According to the MPACT study (Von Hoff DD, et al., New England Journal of Medicine, 2013), gemcitabine+nab-paclitaxel prolonged overall survival compared with gemcitabine alone (8,5 versus 6,7 months; 1-year survival 35% versus 22%). This regimen is positioned as a generally better-tolerated alternative to FOLFIRINOX. Gemcitabine alone may be preferred in patients with lower performance status (ECOG 2 or above).
The regimen combining liposomal irinotecan (see NAPOLI-1 below) with oxaliplatin, folinic acid and 5-FU, NALIRIFOX , based on the NAPOLI 3 study (tested against gemcitabine+nab-paclitaxel in untreated metastatic patients), received FDA approval on 13 February 2024 for first-line metastatic PDAC treatment (overall survival 11,1 versus 9,2 months; progression-free survival 7,4 versus 5,6 months). This is a new use expanding into the first line following liposomal irinotecan's original second-line approval (2015).
Second-Line and Biomarker-Directed Treatment in Metastatic Disease
According to the NAPOLI-1 study (Wang-Gillam A, et al., Lancet, 2016), liposomal irinotecan (nal-IRI) + 5-FU/folinic acid prolonged overall survival compared with 5-FU/folinic acid alone in patients progressing after gemcitabine (6,1 versus 4,2 months; HR 0,57) and received FDA approval on 22 October 2015 as second-line treatment.
According to the POLO study (Golan T, et al., New England Journal of Medicine, 2019), in metastatic patients carrying a germline BRCA1/2 mutation who remained progression-free for at least 16 weeks after first-line platinum-based chemotherapy, maintenance olaparib substantially prolonged progression-free survival (7,4 versus 3,8 months; HR 0,53) and received FDA approval on 30 December 2019 . An important nuance: POLO's subsequently published overall survival analysis showed no statistically significant overall survival difference despite the clear progression-free survival benefit — an important detail showing that olaparib maintenance significantly delays disease progression (detected by imaging), but has not been proven to prolong overall survival.
In the rare MSI-H/dMMR subgroup, pembrolizumab (original tumor-agnostic approval: May 2017), and in the rare NTRK fusion-positive subgroup, larotrectinib (FDA-approved 26 November 2018) or entrectinib (FDA-approved 15 August 2019) may be used regardless of histology — however, these genetic subgroups are very rare in PDAC.
For NRG1 gene fusion-positive disease (seen in approximately 3% of PDAC), zenocutuzumab, a bispecific antibody targeting the HER2/HER3 signaling pathway, based on the eNRGy study (objective response rate 40% in the pancreatic cohort), received accelerated FDA approval on 4 December 2024 — a new development expanding biomarker-directed treatment options in PDAC.
KRAS G12C inhibitors such as sotorasib and adagrasib are FDA-approved for KRAS G12C-mutated lung and colorectal cancer, but there is no separate FDA approval for pancreatic cancer. In the pancreatic cohort (n=38) of the CodeBreaK 100 study, the objective response rate with sotorasib was reported as %21 — substantially lower than the results in lung cancer (%37), demonstrating that the same mutation may show different degrees of efficacy in different cancer types. In addition, G12C accounts for only ~%1-2 of KRAS mutations in PDAC.
Today (26 August 2026), the FDA approved, for the first time, an oral, once-daily "broad-spectrum RAS inhibitor" capable of targeting all major KRAS mutation types (unlike sotorasib/adagrasib, which are specific to just one mutation), daraxonrasib, for patients with metastatic PDAC who have received at least one prior systemic treatment or are unsuitable for multi-drug chemotherapy. According to the phase 3 RASolute 302 study (O'Reilly EM, et al., New England Journal of Medicine, 2026; data first presented at ASCO on 31 May 2026), daraxonrasib approximately doubled overall survival compared with investigator-selected chemotherapy (13,2 months versus 6,7 months; HR 0,40 — approximately %60 reduction in the risk of death) and similarly doubled progression-free survival (~7,2 months versus ~3,5 months). Daraxonrasib was also substantially better tolerated than chemotherapy (treatment discontinuation due to toxicity: %1,2 versus %11,2). This approval is considered a major milestone because it is the first pancreatic-specific targeted therapy that works independently of KRAS mutation type and represents the largest survival difference reported in this disease since the FOLFIRINOX/gemcitabine-nab-paclitaxel era (for more than a decade). The most common side effects are rash, stomatitis (inflammation inside the mouth), diarrhea, nausea, fatigue and edema.
Side Effects of Treatment
| Treatment | Common Side Effects |
|---|---|
| FOLFIRINOX | Bone marrow suppression (neutropenia, risk of febrile neutropenia), diarrhea, nausea/vomiting, fatigue, peripheral neuropathy (oxaliplatin, may be cumulative), mucositis — the most toxic of the regimens, usually administered with growth factor support |
| Gemcitabine + nab-paclitaxel | Bone marrow suppression (particularly neutropenia), fatigue, peripheral neuropathy (nab-paclitaxel), partial hair loss, peripheral edema, nausea |
| Olaparib | Fatigue, nausea, anemia (monitoring/dose adjustment may be required), rare but serious risk of myelodysplastic syndrome/acute myeloid leukemia associated with long-term PARP inhibitor use (class effect, low absolute risk) |
| Liposomal irinotecan (NALIRIFOX/Onivyde) | Diarrhea (may be severe; both acute cholinergic and delayed types — requires proactive management), neutropenia, nausea/vomiting, fatigue |
| Daraxonrasib | Rash, stomatitis (inflammation inside the mouth), diarrhea, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, bleeding — generally better tolerated than chemotherapy |
Supportive Treatments
Relieving Biliary Obstruction
In obstructive jaundice, the primary approach is endoscopic biliary stent placement via ERCP ; when the endoscopic method fails or cannot be performed, percutaneous transhepatic biliary drainage (PTBD) is an alternative option. Our separate article on bile duct stents and PTC drains discusses this topic in detail.
Pancreatic Enzyme Replacement Therapy (PERT)
Exocrine insufficiency/malabsorption (steatorrhea, manifested by greasy, foul-smelling stools), which may develop after pancreatic head resection or when the tumor displaces much of the pancreatic parenchyma, is managed with pancreatic enzyme replacement therapy (PERT) taken with meals. Our separate article on the importance of nutritional support and enzyme replacement discusses this topic in detail.
Management of New-Onset Diabetes
Diabetes developing after pancreatic cancer or surgery is generally called "type 3c (pancreatogenic) diabetes" and may behave differently from typical type 2 diabetes — it may be more brittle and may sometimes require insulin treatment directly, even without a prior history of diabetes.
Pain Management and Nutritional Support
For refractory abdominal/back pain due to tumor invasion of the celiac plexus/retroperitoneum, EUS- or CT-guided celiac plexus block/neurolysis offers an important pain control option. Given the severe weight loss/cachexia syndrome characteristic of pancreatic cancer, dietitian-guided nutritional support and PERT optimization should be an integral part of the treatment plan.
Global Approval and Evidence Timeline
FDA Approval of Liposomal Irinotecan (NAPOLI-1)
Approval as second-line treatment for gemcitabine-refractory metastatic disease.
FDA Approval of Olaparib Maintenance (POLO)Milestone
Approval as maintenance treatment for germline BRCA-mutated metastatic disease — the first biomarker-directed targeted therapy in PDAC.
FDA Approval of NALIRIFOX
The liposomal irinotecan-based NALIRIFOX regimen was expanded to first-line metastatic treatment.
FDA Approval of Zenocutuzumab (Bizengri)
Accelerated approval for NRG1 fusion-positive disease.
FDA Approval of Daraxonrasib (Rasonque)Latest
The first broad-spectrum RAS inhibitor to work independently of mutation type — a groundbreaking improvement in overall survival.
Status in Türkiye: TİTCK Licensing and SGK Reimbursement
The components of FOLFIRINOX (5-FU, folinic acid, irinotecan, oxaliplatin), gemcitabine and capecitabine are widely available in Türkiye under numerous domestic/generic brands and are reimbursed by SGK without an additional restriction specific to pancreatic cancer.
Nab-paclitaxel is not available in Türkiye as a standard domestically licensed product; it is supplied under "overseas medicine (YDI)" status through importation by the Turkish Pharmacists' Association. While some sources describe the SUT provision as "not reimbursed," patients are reported to face substantial uncovered costs (tens of thousands of TL per month), with access largely obtained through individual applications/litigation. This is a striking finding showing that a component of a "standard, first-line" regimen may have much more restricted access in Türkiye than expected; patients and physicians should confirm the current status through SGK/TİTCK sources.
As of the date of this research, no evidence was found that liposomal irinotecan (Onivyde) is commercially available in Türkiye or licensed by TİTCK. Patients and physicians should confirm the current status through TİTCK sources.
Olaparib is licensed by TİTCK in Türkiye and its clinical use is recognized for various indications such as ovarian, breast, prostate and pancreatic cancer; however, SGK reimbursement is limited to maintenance treatment for BRCA-mutated, platinum-sensitive ovarian cancer. Breast, prostate and pancreatic indications are reported to be uncovered by SGK; a lawsuit filed for the prostate cancer indication is documented to have concluded in the patient's favor — suggesting that a similar legal process may also be necessary for the pancreatic indication (this pattern has previously been observed in our project for other drugs too — for example, pembrolizumab, some of whose indications are covered while others are not).
SGK covers pembrolizumab only for 6 named indications (melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, classical Hodgkin lymphoma, squamous head and neck cancer); the MSI-H/dMMR tumor-agnostic indication is outside this list. Consequently, MSI-H pancreatic cancer falls entirely outside the 6 named indications and is not covered by reimbursement in practice.
Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) are licensed by TİTCK in Türkiye; the lack of SGK reimbursement for entrectinib and the need for access through litigation have been confirmed (the reimbursement status of larotrectinib could not be definitively confirmed in this research). Sotorasib (Lumykras) is licensed by TİTCK, but only for the lung cancer indication; SGK does not cover this drug either. No evidence was found that adagrasib (Krazati) is licensed in Türkiye. Since none of these drugs has a pancreatic cancer-specific FDA approval in any case, access for Turkish patients in this subgroup remains largely theoretical.
Numerous domestic brands such as Kreon, Pacrea, Pankraza, Festal N and Pankreoflat are available in Türkiye and are generally reimbursed by SGK (according to some sources, exclusion from coverage may apply only to certain package/dose presentations). This is the best-covered category among the drugs discussed in the article.
Daraxonrasib is an extremely new drug that received FDA approval just today, on the date this guide was written (26 August 2026); at this stage, there is no information available to assess its TİTCK licensing or SGK reimbursement status in Türkiye. Patients and physicians should follow TİTCK/SGK sources for future developments.
Frequently Asked Questions
- Why is pancreatic cancer detected so late?
- Because the pancreas lies deep within the abdominal cavity and early-stage tumors generally cause nonspecific or mild symptoms (such as indigestion and slight weight loss), only approximately %17 of patients have localized disease at diagnosis; this is one of the main reasons for the disease's low overall survival.
- Does new-onset diabetes always indicate pancreatic cancer?
- No — the overwhelming majority of new-onset diabetes is type 2 diabetes and is unrelated to pancreatic cancer. However, diabetes that develops suddenly over the age of 50 without another risk factor, particularly when accompanied by unexplained weight loss, is a warning sign that should draw a physician's attention.
- Does a normal CA 19-9 result rule out pancreatic cancer?
- No. Approximately %5-10 of the population is Lewis antigen-negative and can never produce CA 19-9 regardless of tumor burden; in these patients, a normal CA 19-9 result does not rule out even advanced disease.
- Should all pancreatic cancer patients undergo germline genetic testing?
- Yes — since 2019, the NCCN guideline has recommended germline genetic testing for all pancreatic cancer patients, regardless of family history; this affects both treatment selection (BRCA/PALB2 positivity) and the family's risk assessment.
- Why is the approval of daraxonrasib considered so important?
- Daraxonrasib is the first broad-spectrum RAS inhibitor that works independently of mutation type rather than being specific to a single KRAS mutation type, and it approximately doubled overall survival in the RASolute 302 study — this is considered the largest survival difference reported in this disease since the FOLFIRINOX/gemcitabine-nab-paclitaxel era.
References:
- Sung H, et al. Global cancer statistics 2024. CA Cancer J Clin. 2026. DOI: 10.3322/caac.70090.
- Siegel RL, et al. Cancer Statistics, 2026. CA Cancer J Clin. 2026. DOI: 10.3322/caac.70043.
- Ohtsuka T, et al. International evidence-based Kyoto guidelines for IPMN. Pancreatology. 2024.
- Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011.
- Conroy T, et al. FOLFIRINOX or gemcitabine as adjuvant therapy (PRODIGE 24/CCTG PA.6). N Engl J Med. 2018.
- Neoptolemos JP, et al. Adjuvant gemcitabine and capecitabine (ESPAC-4). Lancet. 2017.
- Von Hoff DD, et al. Nab-paclitaxel plus gemcitabine (MPACT). N Engl J Med. 2013.
- Versteijne E, et al. Neoadjuvant chemoradiotherapy (PREOPANC). J Clin Oncol. 2020, 2022.
- Hammel P, et al. Chemoradiotherapy vs chemotherapy in locally advanced disease (LAP07). JAMA. 2016.
- Wang-Gillam A, et al. Liposomal irinotecan (NAPOLI-1). Lancet. 2016.
- Golan T, et al. Maintenance olaparib for germline BRCA-mutated pancreatic cancer (POLO). N Engl J Med. 2019.
- O'Reilly EM, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer (RASolute 302). N Engl J Med. 2026.
- FDA approval notices: NALIRIFOX, zenocutuzumab-zbco (Bizengri), daraxonrasib (Rasonque).
- Relevant clauses of Turkey's Healthcare Implementation Communiqué (SUT), TİTCK drug authorization lists.
Was this article helpful?
Your feedback helps us improve our content.
